To the Editor: Tsai and Lian [1] and Furlan et al [2] Reply from the Author independently demonstrated that a deficiency in the activDeficiency of von Willebrand factor-cleaving protease ity of von Willebrand factor-cleaving metalloprotease, (ADAMTS-13) activity should not be considered the sole ADAMTS-13 or the presence of its inhibitory antibodies criterion for administering plasma therapy to patients with causes thrombotic thrombocytopenic purpura. It is unthrombotic microangiopathies (TMA). Actually most paknown whether a similar mechanism occurs in patients tients with different forms of TMA, including genetic who develop thrombotic microangiopathy (TMA) followforms associated with factor H deficiency, referred to the ing organ transplantation. We have recently shown that Italian Registry for Recurrent and Familial hemolytic urethe ADAMTS-13 activity was undetectable in plasma mic syndrome (HUS) and thrombotic thrombocytopenic samples obtained from a patient who developed TMA purpura (TTP) responded to plasma therapy [1] , regardafter receiving a cadaveric renal allograft. Deficiency of less of ADAMTS-13 activity. Thus, restricting plasma inthe protease enzyme occurred in the presence of its inhibifusion or exchange to cases with congenital or acquired tory antibodies. Discontinuation of cyclosporine and daily deficiency of ADAMTS-13 activity would deprive some plasma exchange raised the ADAMTS-13 activity, fol-TMA patients of the only potentially effective treatment. lowed by resolution of the microangiopathic hemolysis Moreover, assays of ADAMTS-13 activity are lengthy and improvement of the graft function [3] . and available only in specialized reference laboratories. Ruggeneti [4] pointed out in an article recently pubThus, plasma therapy should be decided on the basis of lished in Kidney International that restoration of von clinicopathologic observations [2] . Samples for later deWillebrand factor-cleaving protease activity in parallel termination of ADAMTS-13 activity could be collected with disease remission does not necessarily imply that before plasma therapy is started. The activity level may normalization of the protease activity is the determinant influence subsequent therapeutic decisions [3] . Sporadic of response to plasma. We are curious if this is based forms, including posttransplant TMA, are often precipion case studies or solely speculations. In our case, we tated by drugs. In these forms, drug discontinuation and showed that the ADAMTS-13 activity rapidly increased plasma exchange usually rise ADAMTS-13 activity and to 50% or higher after two sessions of plasmapheresis.
remove the inhibitors. In recurrent forms with congenital We further showed that the immunoglobulin G (IgG) ADAMTS-13 deficiency, plasma induces disease remismolecules isolated from the patient's plasma inhibited sion even before, or without, normalizing ADAMTS-13 the ADAMTS-13 activity in normal plasma. During activity [4] . In forms with continuous formation of the disease remission, the IgG molecules isolated from the inhibitor, we and others have seen that the antibody titer patient's plasma showed no inhibitory effect on the decreases immediately after treatment, but returns to ADAMTS-13 activity in normal plasma. We speculate pretreatment values shortly after stopping plasma, after in cases that do not recur [4] . that plasma exchange confers its effectiveness by replen-Lagaaij et al [3] an excellent paper regarding the evaluation of risk factors for late kidney allograft failure that recently appeared in Kidney International. However, we would like To the Editor: Cell migration from the host to the to suggest to the authors to see for the effect of nephron transplanted organ results in chimerism in the organ [1] .
dosing on late allograft failure. Although the authors Chimerism may be detected after gender-mismatched have evaluated body mass index (BMI) (Ͼ25 vs. Յ25) organ transplantation with use of fluorescence in situ as a risk factor and found no significant effect. This may hybridization [2] . To verify the endothelial chimerism, not have become significant as extreme BMI groups were we studied kidney grafts with immunohistochemistry for not considered separately. Meier-Kriesche et al have ABO blood-group antigens and in situ hybridization for observed in their study that the relative risk of graft loss Y chromosome. death censored and uncensored was more in extremes Four male recipients had received living kidney transof BMI compared to other categories. It was evident that of the extreme groups the relative risk of chronic plants from female donors. The blood type of the recipiallograft nephropathy (CAN) was significantly more in ents was type A in all cases, and that of donors were high BMI group [2] . We have observed in our study and type O in two cases and type B in two cases. Needle it has been well reported by others that kidneys with biopsies were performed from 2 to 5 months after kidney insufficient nephron mass for the recipient may be damtransplantation and diagnosed as vascular rejection. Enaged by hyperfiltration injury resulting into proteinuria dothelial cells stained with CD34 were positive for Y and CAN [3] [4] [5] . Thus we feel that if authors can analyze chromosomes, indicating the presence of recipient-type nephron dosing in addition to other well studied risk male cells. These endothelial cells were positively stained factors in this cohort, it would be a significant contribufor recipient-type blood group A. The patients in the tion to the literature. present study have shown that replacement of donor endothelium by recipient cells does occur in vascular Navalkishor Udgiri, Randeep Kashyap, and Mukut Minz Chandigarh, India rejection after kidney transplantation.
